Síndrome de Verner-Morrison (VIPoma)

National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: neuroendocrine and adrenal tumors [internet publication].Texto completo

Pavel M, Öberg K, Falconi M, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020 Jul;31(7):844-60.Texto completo  Resumo

Pavel M, O'Toole D, Costa F, et al; Vienna Consensus Conference participants. ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology. 2016;103(2):172-85. Resumo

1. Soga J, Yakuwa Y. Vipoma/diarrheogenic syndrome: a statistical evaluation of 241 reported cases. J Exp Clin Cancer Res. 1998 Dec;17(4):389-400. Resumo

2. Camera L, Severino R, Faggiano A, et al. Contrast enhanced multi-detector CT and MR findings of a well-differentiated pancreatic vipoma. World J Radiol. 2014 Oct 28;6(10):840-5.Texto completo  Resumo

3. Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017 Oct 1;3(10):1335-42.Texto completo  Resumo

4. Ghaferi AA, Chojnacki KA, Long WD, et al. Pancreatic VIPomas: subject review and one institutional experience. J Gastointest Surg. 2008 Feb;12(2):382-93. Resumo

5. Holst JJ, Fahrenkrug J, Knuhtsen S, et al. Vasoactive intestinal polypeptide (VIP) in the pig pancreas: role of VIPergic nerves in the control of fluid and bicarbonate secretion. Regul Pept. 1984 Apr;8(3):245-59. Resumo

6. Robberecht P, Conlon TP, Gardner JD. Interaction of porcine vasoactive intestinal peptide with dispersed pancreatic acinar cells from the guinea pig: structural requirements for effects of vasoactive intestinal peptide and secretin on cellular adenosine 3':5'-monophosphate. J Biol Chem. 1976 Aug 10;251(15):4635-9. Resumo

7. Barbezat GO, Grossman MI. Intestinal secretion: stimulation by peptides. Science. 1971 Oct 22;174(4007):422-4. Resumo

8. Fahrenkrug J. Transmitter role of vasoactive intestinal peptide. Pharmacol Toxicol. 1993 Jun;72(6):354-63. Resumo

9. Biancani P, Walsh JH, Behar J. Vasoactive intestinal polypeptide: a neurotransmitter for lower esophageal sphincter relaxation. J Clin Invest. 1984 Apr;73(4):963-7.Texto completo  Resumo

10. Usdin TB, Bonner TI, Mezey E. Two receptors for vasoactive intestinal polypeptide with similar specificity and complementary distributions. Endocrinology. 1994 Dec;135(6):2662-80. Resumo

11. Thakker RV, Newey PJ, Walls GV, et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab. 2012 Sep;97(9):2990-3011.Texto completo  Resumo

12. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: neuroendocrine and adrenal tumors [internet publication].Texto completo

13. Vinik AI, Woltering EA, Warner RR, et al. NANETS consensus guidelines for the diagnosis of neuroendocrine tumor. Pancreas. 2010 Aug;39(6):713-34.Texto completo  Resumo

14. Kulke MH, Anthony LB, Bushnell DL, et al. NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas. 2010 Aug;39(6):735-52.Texto completo  Resumo

15. Una Cidon E. Vasoactive intestinal peptide secreting tumour: an overview. World J Gastrointest Oncol. 2022 Apr 15;14(4):808-19.Texto completo  Resumo

16. de Herder WW, Hofland J. Vasoactive intestinal peptide-secreting tumor (VIPoma). 2023 Apr 5. In: Feingold KR, Anawalt B, Blackman MR, et al. eds. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000.Texto completo  Resumo

17. Scottish Neuroendocrine Tumour Group. Consensus guidelines for the management of patients with neuroendocrine tumours​. July 2015 [internet publication].Texto completo

18. Sundin A, Arnold R, Baudin E, et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: radiological, nuclear medicine & hybrid imaging. Neuroendocrinology. 2017;105(3):212-44. Resumo

19. Pavel M, Öberg K, Falconi M, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020 Jul;31(7):844-60.Texto completo  Resumo

20. Hope TA, Bergsland EK, Bozkurt MF, et al. Appropriate use criteria for somatostatin receptor PET imaging in neuroendocrine tumors. J Nucl Med. 2018 Jan;59(1):66-74.Texto completo  Resumo

21. Gabriel M, Decristoforo C, Kendler D, et al. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med. 2007 Apr;48(4):508-18.Texto completo  Resumo

22. Barrio M, Czernin J, Fanti S, et al. The impact of somatostatin receptor-directed PET/CT on the management of patients with neuroendocrine tumor: a systematic review and meta-analysis. J Nucl Med. 2017 May;58(5):756-61.Texto completo  Resumo

23. Ataallah B, Buttar BS, Kulina G, et al. Hypercalcemia in a patient diagnosed with a vasoactive intestinal peptide tumor. Cureus. 2020 Feb 4;12(2):e6882.Texto completo  Resumo

24. Metz DC, Jensen RT. Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology. 2008 Nov;135(5):1469-92.Texto completo  Resumo

25. Modlin IM, Pavel M, Kidd M, et al. Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Aliment Pharmacol Ther. 2010 Jan 15;31(2):169-88.Texto completo  Resumo

26. Oberg K. Chemotherapy and biotherapy in the treatment of neuroendocrine tumours. Ann Oncol. 2001;12 Suppl 2:S111-4. Resumo

27. Maton PN, Gardner JD, Jensen RT. Use of long-acting somatostatin analog SMS 201-995 in patients with pancreatic islet cell tumors. Dig Dis Sci. 1989;34(3 suppl):28-39S. Resumo

28. Howe JR, Merchant NB, Conrad C, et al. The North American Neuroendocrine Tumor Society consensus paper on the surgical management of pancreatic neuroendocrine tumors. Pancreas. 2020 Jan;49(1):1-33. Resumo

29. Pavel M, O'Toole D, Costa F, et al; Vienna Consensus Conference participants. ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology. 2016;103(2):172-85. Resumo

30. Ho AS, Picus J, Darcy MD, et al. Long-term outcome after chemoembolization and embolization of hepatic metastatic lesions from neuroendocrine tumors. AJR Am J Roentgenol. 2007 May;188(5):1201-7.Texto completo  Resumo

31. King J, Quinn R, Glenn DM, et al. Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. Cancer. 2008 Sep 1;113(5):921-9. Resumo

32. Johnston PC, Ardill JE, Johnston BT, et al. Vasoactive intestinal polypeptide secreting pancreatic tumour with hepatic metastases: long term survival after orthotopic liver transplantation. Ir J Med Sci. 2010 Sep;179(3):439-41. Resumo

33. Máthé Z, Tagkalos E, Paul A, et al. Liver transplantation for hepatic metastases of neuroendocrine pancreatic tumors: a survival-based analysis. Transplantation. 2011 Mar 15;91(5):575-82. Resumo

34. Merola E, Panzuto F, Delle Fave G. Antiproliferative effect of somatostatin analogs in advanced gastro-entero-pancreatic neuroendocrine tumors: a systematic review and meta-analysis. Oncotarget. 2017 Jul 11;8(28):46624-34.Texto completo  Resumo

35. Rinke A, Müller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009 Oct 1;27(28):4656-63.Texto completo  Resumo

36. Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011 Feb 10;364(6):501-13. Resumo

37. National Institute for Health and Care Excellence. Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease. June 2017 [internet publication].Texto completo

38. Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011 Feb 10;364(6):514-23.Texto completo  Resumo

39. Capdevila J, Teulé A, Barriuso J, et al. Phase II study of everolimus and octreotide LAR in patients with nonfunctioning gastrointestinal neuroendocrine tumors: the GETNE1003_EVERLAR study. Oncologist. 2019 Jan;24(1):38-46.Texto completo  Resumo

40. Bajetta E, Catena L, Pusceddu S, et al. Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: a 5-year update. Neuroendocrinology. 2018;106(4):307-11. Resumo

41. Moertel CG, Lefkopoulo M, Lipsitz S, et al. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med. 1992 Feb 20;326(8):519-23.Texto completo  Resumo

42. Dilz LM, Denecke T, Steffen IG, et al. Streptozocin/5-fluorouracil chemotherapy is associated with durable response in patients with advanced pancreatic neuroendocrine tumours. Eur J Cancer. 2015 Jul;51(10):1253-62. Resumo

43. Kouvaraki MA, Ajani JA, Hoff P, et al. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol. 2004 Dec 1;22(23):4762-71.Texto completo  Resumo

44. Strosberg JR, Fine RL, Choi J, et al. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer. 2011 Jan 15;117(2):268-75.Texto completo  Resumo

45. Hope TA, Bodei L, Chan JA, et al. NANETS/SNMMI consensus statement on patient selection and appropriate use of (177)Lu-DOTATATE peptide receptor radionuclide therapy. J Nucl Med. 2020 Feb;61(2):222-7.Texto completo  Resumo

46. Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 Trial of (177)Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017 Jan 12;376(2):125-35.Texto completo  Resumo

47. Strosberg JR, Caplin ME, Kunz PL, et al. (177)Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021 Dec;22(12):1752-63. Resumo

48. Nguyen HN, Backes B, Lammert F, et al. Long-term survival after diagnosis of hepatic metastatic VIPoma: report of two cases with disparate courses and review of therapeutic options. Dig Dis Sci. 1999 Jun;44(6):1148-55. Resumo

49. Xu J, Shen L, Zhou Z, et al. Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020 Nov;21(11):1500-12. Resumo

50. Roland CL, Bian A, Mansour JC, et al. Survival impact of malignant pancreatic neuroendocrine and islet cell neoplasm phenotypes. J Surg Oncol. 2012 May;105(6):595-600. Resumo

51. van der Zwan JM, Trama A, Otter R, et al. Rare neuroendocrine tumours: results of the surveillance of rare cancers in Europe project. Eur J Cancer. 2013 Jul;49(11):2565-78. Resumo

52. Perry RR, Vinik AI. Clinical review 72: diagnosis and management of functioning islet cell tumors. J Clin Endocrinol Metab. 1995 Aug;80(8):2273-8. Resumo